BioSpace News Archive

OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three upcoming investor conferences.

Palleon Pharmaceuticals today announced that the company will present at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023.

Aytu BioPharma, Inc. will report financial results for its second quarter fiscal year 2023, ended December 31, 2022, after the market close on Tuesday, February 14, 2023.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its fourth quarter and full year 2022 financial and operating results on Tuesday, February 21, 2023, following the close of trading.

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra™ therapy selection test in the United States.

FSD Pharma Inc. today announces the receipt of a No Objection Letter (“NOL”) from Health Canada regarding the Company’s proposed Phase 1 clinical trial of LUCID-21-302.

Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes, announced the commercial availability of its Revita DMR System™ in Germany.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following conference.

Complete Genomics Inc., a global life science tools leader and subsidiary of MGI Tech Co., Ltd. (“MGI”), today launched new revolutionary products and prices at Advances in Genome Biology and Technology (AGBT) General Meeting.

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced the publication of a new peer-reviewed study validating the clinical utility of the company’s proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit, Immunotherapy Response Score (IRS).